The Board of Pharmacy has received notice of the following product recall. The Board strongly encourages pharmacies to immediately review their quality assurance and recall policies and procedures to determine if any corrective action is required.

American Health Packaging, Inc. is initiating a drug recall to the RETAIL LEVEL for AHP Rifampin Capsules USP, 150 mg, 30 UD; Carton NDC#: 60687-575-21, (Individual Dose NDC: 60687-575-11), for the lot listed below. This recall is being initiated in support of the recall by the manufacturer (Lupin Pharmaceuticals, Inc.) dated January 05, 2024, which included lots that were repackaged by American Health Packaging. Lupin stated that "[Affected] lots are being recalled due to out of specification result observed in assay testing of all [affected] lots and related substance testing (N-Methyl Rifampin impurity) in lot A200816, Expiry: January 2024 during stability study. The reduction in the assay content may result in slight decrease in therapeutic effect (sub-therapeutic response). The toxicological properties of N-Methyl Rifampin impurity have not been extensively studied; thus, the health hazards cannot be conclusively assessed." Rifampin is a semisynthetic antibiotic derivative of rifamycin SV. Rifampin is indicated in the treatment of all forms of tuberculosis. Rifampin is indicated for the treatment of asymptomatic carriers of Neisseria meningitidis to eliminate meningococci from the nasopharynx.

PRODUCT NAME: AHP Rifampin Capsules USP, 150 mg, 30 UD

**NDC NUMBER:** Carton NDC#: 60687-575-21 (Individual Dose NDC: 60687-575-

11)

**LOT NUMBER: 1008111** 

**EXPIRATION DATE:** 01/31/2024

SHIP DATES OF PRODUCT: 05/12/2022 to 05/18/2022